PTC Therapeutics’ Earnings Call Highlights Sephience Surge

PTC Therapeutics ((PTCT)) has held its Q1 earnings call. Read on for the main highlights of the call.

PTC Therapeutics’ latest earnings call struck an upbeat tone, with management highlighting a powerful combination of record revenue, a surging Sephience launch and encouraging progress in key neurological programs. While acknowledging pockets of pressure in its mature Duchenne and Emflaza franchises and a regulatory delay for vatiquinone, executives stressed that topline strength and a solid balance sheet leave the company well positioned for long‑term growth.

Record Revenue Underscore Strong Growth Trajectory

PTC reported total revenue of $273 million for Q1 2026, including $226 million of product revenue, marking a 47% year‑over‑year increase versus Q1 2025. Management framed the quarter as a new high‑water mark for the company’s top line and a clear sign that newer launches are more than offsetting headwinds from legacy products.

Sephience Launch Momentum Drives Topline Upside

Sephience was the centerpiece of the call, delivering $125 million in Q1 revenue, with $112 million from the U.S. and $13 million internationally, and growing 36% quarter over quarter. Executives cited a steady cadence of roughly 140 new prescription starts per month and outlined plans to reach commercial availability in up to 30 countries by year‑end.

Raised 2026 Outlook Signals Confidence in Growth

On the back of the strong start, PTC lifted its 2026 full‑year product revenue guidance to a range of $750 million to $850 million. Total revenue is now expected between $1.08 billion and $1.18 billion, underscoring management’s confidence that Sephience and the broader portfolio can sustain robust growth.

Huntington’s Program Bolstered by Positive Votoplam Data

The company highlighted 24‑month interim results from the PIVOT‑HD study of votoplam, which showed dose‑dependent slowing of Huntington’s disease progression and an average 52% slowing on cUHDRS at 10 mg in Stage 2 patients versus a matched natural history cohort. With a favorable safety profile reported, PTC expressed strong support for the partner‑led Phase III INVEST‑HD trial targeting approximately 770 participants.

Vatiquinone’s New Path Aims to Derisk NDA Resubmission

Following an FDA Type C meeting, PTC outlined a new regulatory path for vatiquinone in Friedreich’s ataxia centered on an open‑label 24‑month study of about 120 patients aged 7 to 21. By pairing this trial with a matched FACOMS natural history control, management believes it can increase the probability of a successful NDA resubmission despite the longer timeline.

Broader Pipeline Advances and New Programs Take Shape

Beyond its lead assets, PTC signaled pipeline momentum with plans to start a Phase I trial of PTC612, an oral NLRP3 inhibitor, in Q2 2026. The company also pointed to ongoing progress in its MSH3 efforts for Huntington’s and myotonic dystrophy type 1, the Phase II‑ready PTC844 DHODH inhibitor, and early‑stage programs in ferroptosis for Parkinson’s and NRF2 activation.

Commercial Execution and Access Support Sephience Adoption

Management emphasized that more than 90% of U.S. PKU centers have now prescribed Sephience, with over 2,200 prescriptions generated globally since launch. Refill behavior was described as strong, discontinuation rates in the low double digits, and U.S. payer policies now cover more than two‑thirds of the population with relatively limited restrictions.

Balance Sheet Strength and Cost Discipline Provide Cushion

As of March 31, 2026, PTC held $1.89 billion in cash, cash equivalents and marketable securities, which executives positioned as a key buffer for ongoing R&D and launch investments. Non‑GAAP R&D expense declined 10% year over year to $90 million, while non‑GAAP SG&A rose modestly to $74 million, reflecting measured spending despite the accelerated commercial push.

Mature DMD Franchise Faces Uncertainty and One‑Time Boost

The Duchenne muscular dystrophy franchise generated $81 million in Q1, with Translarna contributing $59 million including a sizable one‑time government purchase order. Management cautioned that this order is non‑recurring and that future demand for Translarna remains difficult to predict, implying some volatility for this legacy revenue stream.

Emflaza Pressured by Intensifying Generic Competition

Emflaza delivered $22 million in Q1 revenue but is facing continued erosion as multiple generics expand in the U.S. market. Executives signaled that both pricing and volume pressure are expected to persist, further reinforcing the company’s strategic pivot toward newer growth drivers such as Sephience.

Non‑Cash Evrysdi Royalties Highlight Accounting Nuance

PTC also recognized $47 million of royalty revenue from Roche’s reported Evrysdi sales of approximately $585 million. However, management clarified that there are no cash proceeds to the company associated with this royalty, underscoring a notable mismatch investors should monitor between reported earnings and actual cash generation.

Modest Cash Burn and International Access Dependencies

The company’s cash and marketable securities declined from $1.95 billion at year‑end 2025 to $1.89 billion at March 31, a roughly $60 million or 3.1% decrease that management described as manageable. Internationally, Sephience roll‑out showed early success, including Japan moving ahead of schedule, but several major European health technology assessment processes and pricing talks remain pending and may create uneven uptake.

Guidance and Outlook Emphasize Sephience’s Billion‑Dollar Potential

PTC’s updated guidance embeds a record Q1 performance and assumes continued strong uptake of Sephience, with 1,244 commercial patients recorded at quarter‑end and more than 1,500 prescription starts in the period. Management reiterated its view that Sephience can ultimately exceed $2 billion in global sales, supported by expanding country launches, solid refill dynamics, disciplined operating spend and a cash position that provides runway for both commercial scaling and late‑stage clinical execution.

PTC’s earnings call painted the picture of a company in transition from a legacy‑anchored portfolio to one led by Sephience and a maturing neurology pipeline. Despite regulatory delays for vatiquinone and pressure on older franchises, the combination of raised guidance, robust launch metrics and encouraging Huntington’s data left investors with a broadly constructive narrative and a clear set of milestones to watch over the coming quarters.